We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

How to Progress Safe and Effective Cell Therapies for Clinical Use!

Read time: Less than a minute

Sistemic believe cell characterization is an essential element in progressing safe and effective cell therapies for mainstream clinical use.

They offer unique miRNA analytical services that provide reliable and cost-effective, characterization and QC tools that are applicable to all cell systems.

Toward this end, Dr Vincent O’Brien (Chief Scientific Officer) and Dr Verna McErlane (Director of Commercial Operations, International) will present data supporting the utility of miRNA in the provision of superior cell characterization and QC methods at the forthcoming Stem Cells Europe conference (20-21 July 2011, Edinburgh).

Dr. Vincent O’Brien will present a poster entitled; ‘A novel microRNA-based stem cell characterization and monitoring tool’, and Verna McErlane will join: Marilyn Robertson, SSCN; Aidan Courtney, Roslin Cells; Dr. David Hay, Fibromed; and, Michael Leek, Immunosolv, at the Scottish Stem Cell Network (SSCN) Panel showcase, “Progress to Therapy and Market” on Wednesday 20 July at 5pm.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.